Abstract
Neutrophil released peptidyl arginine deiminase 4 (PAD4) converts arginine residues on plasma proteins into citrulline. Here, we developed an assay to quantify citrullinated fibrinogen. We employed a biotin-conjugated phenylglyoxal (biotin-phenylglyoxal (PG)) compound that selectively labels citrulline. Patient samples were derived from a multicenter prospective cohort study that aimed to identify cancer patients at high risk for venous thromboembolism (VTE). Our data show that cancer patients have higher (median 2-fold increased) citrullinated fibrinogen levels when compared to normal human plasma and a cohort of healthy donors. Our results show that citrullination of fibrinogen is a common posttranslational modification in patients with cancer.
Original language | English |
---|---|
Pages (from-to) | 136-140 |
Number of pages | 5 |
Journal | eJHaem |
Volume | 5 |
Issue number | 1 |
DOIs | |
Publication status | Published - 26 Jan 2024 |
Keywords
- cancer
- citrullination
- coagulation
- fibrinogen
- thrombosis